| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Guest Access | Sign In via User Name/Password
|
|
|
|||||||
Guest Access | Sign In via User Name/Password |
|||||||||
* From the Department of Clinical Pharmacology & Therapeutics, Ninewells Hospital & Medical School, University of Dundee, Scotland, UK.
Correspondence to: Brian J. Lipworth, MD, Professor of Allergy & Respiratory Medicine, Department of Clinical Pharmacology & Therapeutics, Ninewells Hospital & Medical School, Dundee, Scotland, UK; e-mail: b.j.lipworth{at}dundee.ac.uk
Background: Inhaled corticosteroids such as fluticasone propionate (FP) have dose-related systemic effects, including adrenal suppression. We have therefore investigated the effect of adding a large volume spacer on the systemic bioactivity of FP given via a pressurized metered-dose inhaler (pMDI).
Methods: Fourteen healthy volunteers (mean age, 29.9 years old) were studied using an open, randomized, placebo-controlled, three-way crossover design. Single doses of the following were given at 5:00 PM in a randomized sequence: (1) eight puffs of FP by pMDI, 1.76 mg (250 µg ex-valve, 220 µg ex-actuator); (2) eight puffs of FP by pMDI, 250 µg, with 750-mL spacer (Volumatic; Allen & Hanburys; Uxbridge, UK); and (3) eight puffs of placebo by pMDI. Measurements were made after each dose, including overnight and early morning urinary cortisol/creatinine ratios and 8:00 AM serum cortisol.
Results: Significant (p < 0.05) suppression of all three end points occurred with each active treatment compared to treatment with placebo. Furthermore, significant (p < 0.05) additional suppression occurred when comparing FP by pMDI alone to FP by pMDI with spacer. Geometric mean fold differences (95% confidence interval for fold difference) between FP by pMDI alone and FP by pMDI with spacer were 1.94-fold (1.00–3.78) for overnight urinary cortisol/creatinine ratio and 1.98-fold (1.26–3.10) for 8:00 AM serum cortisol. This was mirrored by a twofold rise in the number of values for uncorrected overnight urinary cortisol < 10 nmol/10 h: placebo treatment (none of 14 subjects); FP by pMDI (6 of 14 subjects; 43%); and FP by pMDI with spacer (12 of 14 subjects; 86%).
Conclusions: The use of a large volume spacer with FP by pMDI results in a twofold increase in the systemic bioavailability as assessed by sensitive measures of adrenal suppression. This, in turn, reflects a twofold improvement in respirable dose delivery with the spacer device.
Key Words: adrenal suppression • asthma • fluticasone propionate • inhaled corticosteroids • spacer
This article has been cited by other articles:
|
|
 |
|
  G. P. Chrousos, L. Ghaly, A. Shedden, D. G. Iezzoni, and A. G. Harris Effects of Mometasone Furoate Dry Powder Inhaler and Beclomethasone Dipropionate Hydrofluoroalkane and Chlorofluorocarbon on the Hypothalamic-Pituitary-Adrenal Axis in Asthmatic Subjects Chest, July 1, 2005; 128(1): 70 - 77. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. S. Fink, L. N. Pierre, P. T. Daley-Yates, D. H. Richards, A. Gibson, and J. W. Honour Hypothalamic-Pituitary-Adrenal Axis Function after Inhaled Corticosteroids: Unreliability of Urinary Free Cortisol Estimation J. Clin. Endocrinol. Metab., October 1, 2002; 87(10): 4541 - 4546. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B J Lipworth, R J Meijer, and H A M Kerstjens Conventional RIA underestimates cortisol suppression in the presence of prednisolone Thorax, September 1, 2002; 57(9): 837 - 837. [Full Text]
|
|
|
|
|
|
B J LIPWORTH, A M WILSON, H S R HOSKER, J M TUGGEY, S P L MEGHJEE, and J S WHITE Montelukast and Churg-Strauss syndrome Thorax, March 1, 2001; 56(3): 244 - 244. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
